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Abstract
Progress made in malaria control during the past decade has prompted increasing global
dialogue on malaria elimination and eradication. The product development pipeline for
malaria has never been stronger, with promising new tools to detect, treat, and prevent
malaria, including innovative diagnostics, medicines, vaccines, vector control products, and
improved mechanisms for surveillance and response. There are at least 25 projects in the
global malaria vaccine pipeline, as well as 47 medicines and 13 vector control products. In
addition, there are several next-generation diagnostic tools and reference methods cur-
rently in development, with many expected to be introduced in the next decade. The devel-
opment and adoption of these tools, bolstered by strategies that ensure rapid uptake in
target populations, intensified mechanisms for information management, surveillance, and
response, and continued financial and political commitment are all essential to achieving
global eradication.
Introduction
The past decade has seen considerable progress in reducing preventable mortality in low- and
middle-income countries (LMICs), as evidenced by the 50% reduction in childhood deaths,
25% reduction in malaria cases, and the World Health Organization (WHO) certification of
four countries as malaria-free [1]. This progress has led to continued optimism and commit-
ments by global and regional partners to commit to malaria elimination and eradication within
a generation. WHO’s Global Technical Strategy for Malaria (GTS), recently endorsed by the
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World Health Assembly in 2015, and the Roll Back Malaria (RBM) Partnership’s Action and
Investment to defeat Malaria (AIM) have embraced the goal of a “world free of malaria” and
have put forward ambitious targets of reducing malaria case incidence and mortality rates glob-
ally by at least 90% by 2030.
However, there remain an estimated 3.2 billion people in 97 countries and territories at risk
of malaria infection. About 214 million malaria cases were estimated to occur in 2015, leading
to 438,000 deaths, and key challenges exist to sustaining and improving on recent gains [1].
Research-and-development spending on drugs, vaccines, and basic research more than qua-
drupled between 1993 and 2013, reaching US$550 million annually. However, continued
investment in research and development and rapid deployment of new tools is needed (see
Box 1). The plasticity of the mosquito and the Plasmodium parasite has led to increasing resis-
tance to medicines and insecticides. Resistance to artemisinin-based combination therapies
(ACTs) has been detected in five countries in Southeast Asia. The spread of these strains to
Africa or the Indian subcontinent could be catastrophic. In Africa, resistance has been detected
against two or more insecticides in two-thirds of countries where malaria is endemic. Up to
80% of infections are asymptomatic, and Plasmodium vivax parasites remain dormant for
months or even years after initial infection. Current field tests are not sensitive enough to pick
up the low density of parasites in low-transmission areas.
As transmission decreases, it is increasingly clustered in at-risk populations such as forest
workers, who often migrate among job sites, taking the disease with them; or geographically
resistant areas or “hotspots” such as swamps and other sources of stagnant water that serve as
breeding sites.
The Lancet Commission on Investing for Health determined that if the right investments
are made in scaling up existing health interventions and in developing new prevention, treat-
ment, and surveillance tools, the world could achieve a “grand convergence” by 2035, with pre-
ventable deaths reaching universally low levels and economic benefits exceeding cost by a
factor of 9–20 [2]. Historically, LMICs that have aggressively adopted new tools have seen an
additional 2%-per-year decline in child mortality rates compared with nonadopters [2]. How-
ever, adoption alone of new and existing tools with poor implementation will have little impact
on disease transmission in the long term. The difficulty of maintaining major declines in
Box 1. Five Key Papers in the Field
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disease following effective malaria control initiatives underscores the fragility of these successes
[3]. Sustained success will require the combination of universal coverage of interventions with
implementation of a robust surveillance system that collects, transmits, and analyzes data
about cases and program activities in real time to inform rapid response strategies [4–6]. How-
ever, detection and response remain serious operational challenges in resource-constrained set-
tings plagued by weak health and information systems and uncertain funding streams.
Effective and efficient scale-up of existing interventions is required, which includes the early
treatment of malaria cases with ACTs, intermittent preventive treatment for pregnant women
(IPTp), and interventions that reduce human–vector contact, such as indoor residual spraying
(IRS) or use of long-lasting insecticide-treated bed nets (LLINs).
Gains will require not only new approaches for scaling up existing strategies for malaria
treatment and prevention to address areas of high malaria transmission and interrupt parasite
transmission, but also novel tools to counter the growing threat of drug and insecticide resis-
tance and better surveillance mechanisms to more efficiently target interventions to popula-
tions and areas of high risk of malaria transmission.
We describe the tools and strategies that are currently being used, as well as those on the
near-term horizon, that have the potential to accelerate the decrease in malaria mortality and,
thus, bend the curve. We also identify opportunities and gaps in current research.
Potential Game Changers on the Horizon
The current malaria landscape offers both opportunities and threats. Amongst the opportuni-
ties are new products that provide a step change in our ability to diagnose, prevent, or treat
malaria (Fig 1). There are many threats, but the most significant is that selective pressure will
result in drug-resistant parasites or insecticide-resistant vectors that reduce the effectiveness of
existing interventions. Malaria control and elimination demand new tools and technologies as
well as better mechanisms for maintaining detailed surveillance and spatial decision support
systems (SDSS) that improve reporting and timeliness of activities [7].
The majority of new products currently under development are in partnership with Product
Development Partnerships (PDPs) such as the Program for Appropriate Technology in Health
(PATH); Malaria Vaccine Initiative (MVI), Medicines for Malaria Venture (MMV), the Inno-
vative Vector Control Consortium (IVCC), the Foundation for Innovative New Diagnostics
(FIND), Novartis Institute for Tropical Diseases (NITD), Drugs for Neglected Diseases Initia-
tives (DNDi), and the European Vaccines Initiative (EVI).
There are over 100 products in the research and development pipeline that will benefit
regional elimination and global eradication goals. These range from innovative diagnostics,
medicines, vaccines, and vector control products to improved mechanisms for surveillance and
targeted responses. Many of these promising products are expected to be introduced within the
next ten years (Fig 1).
Diagnostics
Improved diagnostics are needed to monitor and measure changes in infection rates, assure the
quality of medicines and insecticides, and measure characteristics that drive treatment choice.
Current-generation Rapid Diagnostic Tests (RDTs) are excellent for diagnosing people with
symptomatic malaria, who have relatively high parasite densities. They have expanded access
to malaria diagnosis outside health facilities to more peripheral communities beyond the reach
of microscopy. However, a critical step in reducing the infectious burden of the disease is miss-
ing: current tests cannot detect either the low-level blood-stage infections of any malaria spe-
cies or the dormant liver stages of P. vivax and P. ovale [8]. A highly sensitive point-of-care
Tools for malaria elimination
PLOS Biology | DOI:10.1371/journal.pbio.1002380 March 2, 2016 3 / 14
field test is needed to rapidly detect low-density parasitemia and identify all infected individu-
als, enabling immediate treatment.
In addition, improved point-of-care diagnostics for other causes of fever, particularly multi-
plexed with malaria tests, will be increasingly important to address the burden of other acute
febrile disease and, in so doing, maintain the viability and legitimacy of the continued intensive
screening for malaria necessary to drive down residual transmission.
Point of Care G6PD Deficiency Tests
P. vivax can be cured by 8-amino quinolones, such as primaquine [8]. However, treating
G6PD-deficient patients with primaquine is associated with a risk of acute hemolytic anaemia.
Fig 1. Projected time periods for introduction of novel malaria technology. Accelerating toward eradication through innovative tools that monitor
(surveillance), prevent (vector control, vaccines), and treat (drugs, diagnostics) malaria.
doi:10.1371/journal.pbio.1002380.g001
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As such, it is necessary to detect individuals deficient in the G6PD enzyme to facilitate safe and
effective treatment in patients with P. vivax. These tests are currently available only in limited
facilities [9]. The immediate availability of information on enzyme deficiency, through rapid
testing and good access to data, will enable the scale-up of effective P. vivax treatments to drive
malaria transmission down.
Next Generation RDTs and Screening Tests
The Infection Detection Test (IDT) is aimed at a limit of detection an order of magnitude
lower than that of current RDTs while maintaining affordability and ease of use. It has the
potential to detect infections hidden from current case management tests and plays a major
role in elimination settings. The development of field-deployable survey tools such as serology
and parasite-detecting tests that can identify population hot spots will enable more effective
targeting of intensive screening, mass drug administration, and other interventions aimed at
residual foci of transmission.
Reference Methods
As countries approach malaria elimination, the proportion of low-density and asymptomatic
infections increases, and new reference standards that detect antigens, nucleic acids, or other
biomarkers are needed for diagnosis and tracking changes in the rate of malaria infections.
There are two main molecular methods available: Loop-mediated isothermal amplification
(LAMP) and polymerase chain reaction (PCR). These are capable of detecting low-density
parasitemia, while PCR may also distinguish between local and imported cases. While their
field applicability remains limited, the cost and complexity of these assays are decreasing.
Insecticide Quantification Kits
Simple point-of-use kits have been developed to allow quality assurance of insecticide formula-
tions and field-based measurement of IRS quality. These need to replace insecticide bioassay
methods, which are impractical in resource-limited public health systems and rarely used in
operational programs despite being recommended as the gold standard.
Medicines for the Treatment and Prevention of Malaria
The overall goal of new medicines is twofold. First, it is important to have new medicines avail-
able that are active against emerging resistant strains of the parasite. Second, as part of the
malaria elimination agenda, simpler courses of treatment would be useful. Over the last decade,
five new fixed-dose ACTs have been launched, of which only one (artemether-lumefantrine) is
available as a child-friendly taste-masked formulation. Over the next few years, more pediatric
ACT versions will be launched. The availability of five different partner drugs is essential: part-
ner drug resistance is increasingly common, and, thus, a range of options are needed. Looking
to the future, there is still scope for improvement. Current treatments are taken over three
days, and compliance with the full course of treatment is poor. A malaria medication allowing
a single-dose cure, and, therefore, directly observed therapy, would be ideal. In addition, the
relative importance of P. vivax infections is rising: P. vivax develops dormant forms or hypno-
zoites, which result in multiple malaria episodes from a single infection. The ideal medicine for
treatment would therefore have activity against the asexual and sexual blood stages of the para-
site as well as against the hypnozoites where present (P. vivax and P. ovale). In high-transmis-
sion areas, such a medicine could provide post-treatment prophylaxis, providing a period of
protection for a child after treatment. Although an ambitious target, a single-encounter, radical
Tools for malaria elimination
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cure would be of great benefit in malaria elimination, circumventing many issues on cost, logis-
tical management, and adherence issues [10,11]. One critical success factor is that any new
compound being developed must be active against preexisting resistant strains. There is also a
need for cost-effective malaria chemoprophylaxis for vulnerable groups such as small infants
and pregnant women. Increasingly, as the eradication agenda proceeds, there will be a need to
protect people from malaria-free districts travelling to areas of high endemicity: for example, in
Zambia, travelers from the south of the country are hardly exposed to infection, have little
immune protection, and, thus, are at a high risk of infection when travelling to the highly
endemic north.
New Blood Schizonticides in Phase II
Currently, there are four new medicines that have reached clinical Phase II, where they have
been shown to be active in curing malaria: OZ439, a third-generation endoperoxide; KAE609, an
inhibitor of the parasite sodium channel PfATP4; KAF156, whose mechanism of resistance
includes the previously unannotated cyclic amine resistance locus; and DSM265, an inhibitor of
the parasite dihydroxyorotate dehydrogenase (DHODH). All four products, which have been
discovered within the last decade, are fully active against primary clinical isolates, including the
recently characterized artemisinin-resistant strains [12]. They are all relatively fast-acting com-
pounds, but, in contrast to artemisinin, all compounds have long half-lives and show potential to
give coverage for over a week from a single dose. The challenge moving forward is to identify the
best possible combinations. One option is to go with existing partner drugs such as piperaquine,
which is well understood clinically, but for which resistant field isolates exist. The second option
is to partner with newer members of the old families: ferroquine or pyronaridine, which have
lower risk of resistance. The final option is to pair two new drugs. All three approaches are being
considered in the current development pipeline: OZ439 is being tested in a Phase IIb combina-
tion trial with piperaquine and is about to be tested in another with ferroquine, both in partner-
ship between MMV and Sanofi. Early combination studies with OZ439 and DSM265 are being
carried out in controlled human infection models. KAE609 combination studies are planned for
2016 by MMV and Novartis, although the partner drug strategy has not been finalized.
Transmission Blocking: Low-Dose Primaquine and Beyond
Artemisinin combination therapies are not active against the late-stage (Stage V) gametocytes,
and patients can still carry infectious gametocytes even though they are cured of the asexual
forms of the parasite. Primaquine has been shown to be active against these gametocytes with a
single low dose of 0.25 mg/kg. In October 2012, WHO released an updated policy recommen-
dation, endorsing this regimen in addition to ACTs [13,14]. In contrast, a 2012 Cochrane
report concluded that there was not sufficient evidence to determine whether primaquine
reduces gametocyte prevalence and density enough to have an effect on transmission in com-
munities where many infected individuals are asymptomatic [8]. Recent reviews of primaquine
in G6PD-deficient patients suggest that the single low dose of primaquine is unlikely to cause
hemolysis [15], although safety concerns were sufficient that the more effective, higher dose of
0.75 mg/kg was not recommended. Several trials, expected to be reported in 2016, are under-
way to provide additional evidence that adding a single low-dose treatment of primaquine to
ACTs can help reduce transmission of P. falciparummalaria, as outlined in the Primaquine
Roadmap developed by the Malaria Elimination Initiative of the University of California, San
Francisco [16]. The newer medicines in the development pipeline have activity in vitro in stan-
dard membrane feeding assays (SMFA) at concentrations similar to those achieved clinically.
Studies in controlled human malaria infection (CHMI) models are ongoing to confirm whether
Tools for malaria elimination
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this activity is seen clinically. If so, the newer generation of drugs could be seen to be prima-
quine-sparing, to prolong its global utility as an effective drug, or, at best, prevent transmission
without any need for primaquine.
Tafenoquine
The relapses caused by activation of hypnozoites of P. vivax can be prevented by a 14-day
course of primaquine. This obviously presents issues with compliance in asymptomatic
patients. In addition, this regimen carries with it a risk of hemolysis in G6PD-deficient patients.
Tafenoquine, a new medicine based on the same 8-aminoquinoline scaffold, originally discov-
ered by the Walter Reed Army Institute of Research (WRAIR), has recently shown great prom-
ise in Phase II trials and is currently being tested in pivotal Phase III trials by GlaxoSmithKline
in partnership with MMV [17]. Tafenoquine use would still require a G6PD diagnostic test.
The search for new molecules that can be used to kill hypnozoites without the need for such a
test is being intensified, although so far no candidates have been identified.
Seasonal Malaria Chemoprevention (SMC)
SMC involves administration of treatment on a monthly basis to coincide with the annual peak
in malaria transmission. This intervention is highly effective in reducing the incidence of clini-
cal malaria and anemia in young children, and, in 2012, WHO recommended implementation
of SMC for children under the age of five in areas of the Sahel subregion of Africa with highly
seasonal transmission. This recommendation is now being implemented increasingly in coun-
tries of the Sahel. Although less extensively researched, and not yet recommended by WHO,
evidence suggests that SMC is as effective in older children [18].
Table 1 contains a description of the potential global drug pipeline in July 2015. Forty-seven
medicines are at varying stages in development, with those in translational and developmental
phases given in Table 1 [11, 19, 20].
Vaccines
Vaccines are generally classified into three approaches: pre-erythrocytic vaccines aim to pre-
vent blood-stage infection; blood-stage vaccines aim to clear parasitaemia and prevent clinical
disease; and transmission-blocking vaccines aim to prevent infection of mosquitoes and inter-
rupt malaria transmission in populations. There is a growing appreciation that vaccines com-
bining multiple targets and stages will be required for achieving and sustaining elimination.
Table 1. Global drug pipeline.
Preclinical Phase I Phase II Phase III
Oxaboroles Sevuparin KAE609 Trimethoprim-sulfamethoxazole
P218 ACT451840 OZ439 + piperaquine Tafenoquine
PA21A092 MMV390048 Fosmidomycin + piperaquine
NPC1161B CDRI 97/78 OZ439 + ferroquine
SJ557733 Methylene blue
DDD107498 AQ13
GSK030 DSM265
AZ412 KAF156
Artemisone
doi:10.1371/journal.pbio.1002380.t001
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The development of effective malaria vaccines has been a major goal of the malaria research
community for many decades. In 2006, the global Malaria Vaccine Technology Roadmap
established the goal of developing an 80%-effective vaccine against P. falciparummalaria by
2025 that would provide protection for longer than four years, with an interim landmark of a
50%-effective vaccine of one-year duration by 2015 [21]. The new Technology Roadmap
updated in 2012 outlines that by 2030, vaccines should be developed that provide at least 75%
protective efficacy against clinical malaria, reduce transmission of the parasite, and can be
deployed in mass campaigns [22].
Because of the complex life cycle of the Plasmodium parasite, host immune response efforts
have been focused most recently on the pre-erythrocytic stage of infection to protect against
the early stage of malaria infection and thereby block disease progression to red blood cells and
clinical malaria [23]. Still, the potential of transmission-blocking vaccines and the need for P.
vivax vaccines in malaria elimination is increasingly being recognized.
RTS,S, a pre-erythrocytic vaccine for the prevention of clinical P. falciparummalaria in chil-
dren, is the first vaccine to successfully complete a Phase III clinical trial. The vaccine has
recently been approved by the European Medicines Agency, and WHO was imminently
expected to make the first malaria vaccine policy recommendations. The trials, conducted in
African children, demonstrated a vaccine efficacy for clinical malaria of 50% in children aged
5–17 months old but only 30% in infants, the target population [24]. While RTS,S demon-
strates that a malaria vaccine is possible, an ideal candidate to support global eradication efforts
would need to have a higher efficacy [25].
A highly effective transmission-blocking vaccine with the ability to interrupt transmission
of the Plasmodium parasite from infected humans to naïve mosquitoes would be a key tool for
malaria elimination [26], but such a vaccine would require an extensive research-and-develop-
ment agenda. This includes consensus among experts regarding the clinical and entomological
metrics required to assess whether a change in transmission has occurred, as well as the tools
needed to effectively measure the end point of reduced transmission of parasites to mosquitoes.
A standalone transmission-blocking vaccine offers protection at the community level, but does
not offer the vaccinated individual protection against becoming infected by Plasmodium.
Therefore, the ideal vaccine would be a combination of vaccines that protects individuals
against disease and/or Plasmodium infection and stops transmission of multiple species (and
strains), especially the most widespread, P. falciparum and P. vivax. Such combination vaccines
are yet to be developed and will not be commercially available in the next decade (Table 2).
Table 2. Current malaria vaccine clinical trial pipeline.
Vaccine type Phase Ia Phase Ib Phase IIa Phase IIb Phase III
ChAd63/MVA ME-TRAP + Matrix M Ad35.CS Ad35.CS/RTS,S-AS01 ChAd63/MA ME-TRAP RTS,S-AS01
Pre-erythrocytic Polyepitope DNA EP 1300 PfSPZ AD35.CS/Ad26.CS
PfCelTOS FMP012 ChAd63/MCA
CSVAC M3V.Ad.PfCA
M3v.d/Ad.PfCA
ChAd63.AMA/MVA.AMA1 + AI/CPG7909 EBA 175.R2 ChAd63/MVA MSP 1 GMZ2
Blood Stage SR11.1 SE36 ChAd63.AMA1/MVA.AMA1 MSP3
ChAd63/MVA PvDBP * FMP2.1-AS01B
Transmission-blocking Pfs25-EPA
Pfs25-VLP
* Targets P. vivax
doi:10.1371/journal.pbio.1002380.t002
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Of the 25 malaria vaccine projects in global development, four are in Phase IIb or III trials
[26,27]. All but one current vaccine candidate target P. falciparum alone, which will likely not
be sufficient given the increasing proportion of patients with P. vivax or mixed infections.
Then, there are three other species to be considered: P.malariae, P. ovale, and P. knowlesi, the
latter being a zoonotic species.
Public Health Insecticides
Pyrethroids developed in the 1970s and 1980s are predominantly used for IRS and LLINs. As
these interventions have been scaled up, particularly in Africa, over the last decade, pyrethroid
resistance has gone from rare frequency and low-level in Anopheles gambiae to Africa-wide
and high-level, and, in some instances, greater than 1,000-fold levels of resistance compared to
susceptible insects [28]. The IVCC was established in 2005 in response to the problem of insec-
ticide resistance and the pressing need for an alternative long-lasting insecticide. The portfolio
of products since established is given in Table 3. Syngenta, in collaboration with the IVCC, has
reformulated an organophosphate insecticide, Actellic 300CS, to double the longevity of the
effective treatment period [29,30]. This product is rapidly replacing pyrethroids for IRS, but, as
the product is inherently more expensive, it has cost implications. In addition, replacing one
monotherapy, which is the exclusive use of one chemical class, with another will inevitably lead
to the failure of this insecticide without careful management [31].
The urgent requirement is to bring new chemistry to the public health insecticide market.
Three new insecticides will be developed from a portfolio of at least nine novel chemistries cur-
rently under evaluation [32]. The Innovation to Impact initiative brings together multiple
stakeholders to identify mechanisms to effectively shorten the development and registration
times for these new products so they reach the market sooner.
It may be possible to reduce selection for resistance with effective integrated vector con-
trol. While this strategy is widely promoted, its scale-up potential is limited. Both IRS and
LLINs target mosquitoes that bite and rest indoors, but these mainstream interventions do
not affect residual outdoor transmission, which is significant in some areas [32,33]. The larg-
est gap in the vector control portfolio is an intervention that can be used at scale to target out-
door resting and outdoor biting mosquito populations. While a number of possible products
Table 3. Current vector control pipeline.
Application Research Field Testing WHO Pesticide Evaluation Scheme
(WHOPES) Testing
Indoor Residual Spray Chlofenapyr
Long-Lasting Indoor Residual
Spray
Alphacypermethrin
SB
Long-Lasting Insecticide-Treated
Bednet
Repurposed active ingredients from crop
protection
Akanet LN Chlorfenapyr/pyrethroid
New active ingredients Miranet LN Pyriproxyfen/pyrethroid
Repurposed crop protection compounds Olyset Duo LN DawaPlus 2.0 LN
Panda Net 2.0 LN Olyset Plus LN*
Veeralin LN PermaNet 3.0 LN*
Yahe LN
ITN Treatment Kit ICON MAXX*
Larvacide VectoMax GR
* WHOPES Testing and Evaluation Phase III
doi:10.1371/journal.pbio.1002380.t003
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are being evaluated for the outdoor market, there is no single obviously scalable intervention
that can be recommended today.
Other Potential Vector Control Methods
A variety of other noninsecticidal intervention methods are under development. These include
novel genetic approaches and inheritable bacterial endosymbionts. Insects in which the nuclear
genome of maternally inherited endosymbionts, such as Wolbachia, have been altered, are
released into the target field populations of Anopheles. These approaches aim to reduce trans-
mission by reducing the population size, lifespan, or ability to transmit the malaria parasite. To
date, Aedesmosquitoes have proven more tractable to these approaches, with large-scale field
trials underway to test the feasibility of Wolbachia or tetracycline-sensitive lethal positive feed-
back loops. In Anopheles, progress is being made with homing endonuclease genes (HEGs)
[34]. However, mainstream adoption of these tools and technologies is still a mid-term rather
than a short-term goal.
Surveillance and Response
In countries that have reached the elimination stage, defined by WHO as those with less than
one diagnosed case of malaria per 1,000 people at risk per year, strong surveillance systems are
critical to prevent outbreaks. As malaria transmission declines, cases become concentrated in
at-risk populations (“hot pops”) or regions (“hot spots”). Epidemiological surveillance is
needed to detect “hot pops” and “hot spots,” which can then be targeted for enhanced malaria
control. Surveillance in the elimination context strives to identify and respond promptly to
every malaria case, ideally within 24 hours [35]. Several key features characterize an ideal sur-
veillance system for malaria elimination.
Reporting and case investigation must be rapid and complete to identify symptomatic and
asymptomatic cases and prevent additional malaria infections. This can be achieved using
either active or passive approaches. Passive surveillance may be adequate in areas with histori-
cally low transmission and good access to health facilities. Active case detection may be needed
for hard-to-reach populations who do not attend health facilities, as well as asymptomatic
cases that continue to transmit the parasite in the absence of symptoms.
The most widely adopted surveillance and response approach is reactive case detection
(RACD), whereby household members, neighbors, and other contacts of passively detected
cases are screened for infection and treated with antimalarials [36–38]. China has taken this a
step further and implemented a successful “1-3-7” policy, which defines targets of reporting
individual cases within one day, conducting case confirmation and investigation within three
days, and rolling out appropriate public health response to prevent further transmission within
seven days [39].
Surveillance in an elimination context demands integration of related data, such as census
or health survey information, central data storage and management, automated and expert
data analysis, and customized outputs and feedback that lead to timely and targeted interven-
tions [4–6]. Robust surveillance systems that integrate and synthesize data across multiple
sources and use mobile technology will make actionable data available to decision makers at
the local, district, and national levels in near real time. Ideal surveillance systems leverage tools
like Geographic Information Systems (GIS), spatial modeling, and SDSS to map and predict
malaria transmission risk and guide effective, targeted responses at a local level. In elimination
programs, and in preventing the reintroduction of malaria to eliminated areas, mapping the
risk of receptivity and vulnerability is essential to target surveillance operations. SDSS, which
uses automated analysis of geospatial data related to malaria transmission, holds promise for
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helping countries in pre-elimination and elimination stages use malaria case data to produce
accurate risk maps at finer scales, map intervention coverage, and guide control programs to
improve effectiveness and efficiency [7].
Malaria in high-risk populations constitutes one of the most intractable challenges to con-
trol efforts. An example is in the Greater Mekong subregion, where massive human migration
occurs across porous borders, sustaining and spreading multidrug-resistant P. falciparum
malaria. Often, these groups reside in rural areas with poor access to treatment, are migrant
workers, or are economically or politically marginalized. Patterns of human mobility help give
country managers critical information about the risk of reintroducing the parasite into areas
with little or no malaria.
Surveillance itself is an elimination intervention that reduces transmission if detection of
focal outbreaks and treatment of infections from the infectious reservoir can occur rapidly.
Taken together, the information provided by a robust surveillance and response system allows
resources to be deployed in a timely, targeted, and efficient manner. Operational research to
identify the effectiveness of various surveillance strategies is currently underway.
Mass Drug Administration
Mass screening and treatment using RDTs of populations at high risk of malaria has been
shown to be ineffective at reducing malaria transmission, most likely because of the large pro-
portion of infections that are left undetected and untreated. Parasite densities are usually low
in asymptomatic individuals, and RDTs as well as PCRs from filter paper blood spots lack suffi-
cient sensitivity to detect low densities.
Recently, there has been renewed interest in the empiric administration of a therapeutic
antimalarial regimen to an entire population at the same time, otherwise known as mass drug
administration (MDA). This presumptive antimalarial treatment of targeted populations is
also called targeted malaria elimination (TME) and targeted malaria treatment (TMT), or tar-
geted parasite elimination (TPE). The potential impact of MDA on malaria is large, reducing
the chances of malaria mortality and morbidity through its direct therapeutic or prophylactic
effect on individuals who receive a treatment dose of antimalarials. MDA can reduce transmis-
sion rates by reducing parasitaemia prevalence and interrupting various stages of the parasite
life cycle. Some antimalarial drugs could inhibit the sporogonic cycle in the mosquito, reducing
its vectorial capacity. If every member of a given population is treated by antimalarial MDA, an
immediate reduction in asexual parasite prevalence in the population would result.
A 2013 Cochrane systematic review concluded that MDA of antimalarials appears to sub-
stantially reduce the initial risk of malaria parasitaemia [39], but there remain knowledge gaps,
especially on optimal target population size, methods to improve coverage, and primaquine
safety [40,41].
Targeted MDA will likely be used to block transmission in foci and accelerate the impact of
vector control and access to diagnosis and treatment in malaria elimination programs. One key
issue here is that medicines such as ACTs and primaquine have been registered based on a clin-
ically demonstrated risk:benefit ratio in symptomatic patients. The evidence base for an appro-
priate risk:benefit ratio in asymptomatic or noninfected subjects will need continual attention.
The regimen used for MDA should differ from the first-line treatment in the same area, so
that treatment and prophylactic treatment do not add to the selection pressure for resistance
on a single drug. Current trials use a full course of dihydroartemisinin/piperaquine (DHA-P),
and a single low dose of primaquine is added to the drug combination to abort gametocytae-
mia. Alternative antimalarials, such as artemether combined with lumefantrine, can be con-
sidered, but this partner drug has a shorter half-life. A minimum of three “rounds” of drug
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administration is needed to ensure an impact on transmission. Preliminary data show that
DHA-P is effective in curing asymptomatic parasite carriers, as well as in areas with estab-
lished artemisinin resistance. With no appropriate alternative antimalarials currently avail-
able, there is no real substitute for ACTs for use in TMT. The potential hazard of increasing
drug pressure with ACTs by using a mass drug treatment approach on an already resistant
parasite population is well recognized.
Complicating deployment, it is not known whether many medicines considered for MDA
are safe during first-trimester pregnancy. This presents additional problems if the medicines
are deployed in Africa, where pregnancies are not usually reported in the first trimester.
Getting Ahead of the Resistance Curve
Vigilance for the emergence and spread of drug-resistant parasites and declining treatment effi-
cacy is crucial. While resistance is a major problem, the current response has been reactive
rather than proactive. The resistance phenotypes have to be selected before establishing the
underlying mechanism of the resistance, followed by simplified methodologies to track resis-
tance as it moves through parasites in insect vector populations and to establish the resistance’s
impact on interventions. The advent of modern high-throughput genome sequencing and big
data analytics has opened up the potential for a more proactive approach. Genome sequencing
allows signatures of selection to be identified as soon as a new intervention is used. The ability
to predetermine the genes under selection before an intervention is deployed at scale will allow
the design of effective resistance-management strategies to maximize the efficacy of both medi-
cines and insecticides.
Conclusions
Collectively, the pipeline of new malaria prevention and treatment tools has never been health-
ier. However, the scale at which current treatments are being deployed has facilitated the wide-
spread emergence of resistance, creating an urgent need for better field diagnostic tools and
new methods for quickly, cost-effectively, and accurately detecting and preventing importation
of malaria parasites in low-endemic settings. To ensure that these tools are able to contribute
effectively to rapid reductions in malaria transmission, appropriate scale-up and roll-out strate-
gies must be developed. Better approaches to surveillance will both identify key sources and
pathways of malaria transmission and focus diagnosis, treatment, and prevention resources
where they can be most effective in accelerating parasite elimination and saving lives. New
strategies will also help to identify the most efficient ways to deploy interventions. If these
interventions are properly implemented in an integrated and complementary manner, we will
be able to sustain and build upon the impressive reductions that have been achieved to date,
significantly enhancing the prospects for malaria elimination.
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